ArticleJournal of clinical neurology (Seoul, Korea)2025
Olfactory Dysfunction in Patients With Acetylcholine-Receptor-Antibody-Positive Myasthenia Gravis.
Article in Journal of clinical neurology (Seoul, Korea), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The overlooked side of myasthenia gravis: the non-motor manifestations-a comprehensive review.Journal of neurology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
background and purposeMyasthenia gravis (MG) is an antibody-mediated disease characterized by fluctuating muscle weakness and fatigue due to impaired neuromuscular junction transmission. Although primarily considered a motor dysfunction disorder, there is emerging evidence that MG can also present with nonmotor symptoms, including olfactory impairment. However, the prevalence and clinical relevance of olfactory dysfunction in MG remain poorly understood. This study compared olfactory function between MG patients and healthy controls with the aim of identifying clinical factors associated with olfactory impairment in MG.
methodsAcetylcholine receptor (AChR)-antibody-positive MG patients and healthy controls were recruited from a single-center outpatient clinic. Olfactory function was assessed using the KVSS II (Korean version of the Sniffin' Sticks II) test, comprising odor threshold, discrimination, and identification subtests. We compared olfactory function and clinical factors between MG patients and healthy controls after adjusting and matching for age and sex.
resultsThis study enrolled 51 MG patients and 43 healthy controls. Logistic regression analyses revealed that the MG patients had a significantly increased risk of olfactory dysfunction (odds ratio=3.6, 95% confidence interval=1.4-9.1,
conclusionsOlfactory dysfunction was significantly more prevalent in the MG patients than in the healthy controls. These findings highlight the need for further research into the underlying mechanisms and potential clinical implications of olfactory impairment in MG.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.